Leukæmi kliniske forsøg i Connecticut
11 studier for Leukæmi søger deltagere på steder i Connecticut.
Byer i Connecticut
Officiel studietekst (engelsk)
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, New Haven
RekruttererFase 3
Alder 18 til 18 · Alle køn · Opdateret 8. sep. 2026 · NCT07509151Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Hartford HealthCare Cancer Institute, Hartford
- Yale University School of Medicine, New Haven
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Smilow Cancer Hospital at Yale New Haven, New Haven
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
- Connecticut Children's Medical Center, Hartford
RekruttererObservationsstudie
Op til 30 år · Alle køn · Opdateret 16. jul. 2026 · NCT04968834Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 19 til 110 · Alle køn · Opdateret 29. jun. 2026 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, New Haven
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Yale University, New Haven
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Yale University, New Haven
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT04256317Revumenib in Combination With 7+3 + Midostaurin in AML
- Yale Cancer Center, New Haven
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 25. mar. 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Hartford
- Massive Bio SYNERGY-AI site, Norwalk
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.